Año 2022 / Volumen 114 / Número 6
Original
Comparison of phenotypes and outcomes following resection of incidental versus symptomatic pancreatic neuroendocrine tumors

317-322

DOI: 10.17235/reed.2021.8096/2021

Luis Hurtado-Pardo, Charles E. Breeze, Javier A Cienfuegos, Alberto Benito, Víctor Valentí, Pablo Martí-Cruchaga, Gabriel Zozaya, Fernando Martínez Regueira, Fernando Pardo, Fernando Rotellar Sastre,

Resumen
Background and aim: fifty to 70 percent of pancreatic neuroendocrine tumors are diagnosed incidentally. The objective of this study was to compare the phenotype and oncological outcomes of incidental versus symptomatic pancreatic neuroendocrine tumors. Methods: a retrospective study was performed, identifying all incidental and symptomatic tumors resected between 2000 and 2019. Baseline characteristics, symptoms, operative variables and pathological stage were all recorded. Patterns of recurrence and overall and disease-free survival were analyzed in both groups. Results: fifty-one incidental and 45 symptomatic pancreatic tumor resections were performed. Symptomatic tumors were more frequent in females (29 vs 17; p = 0.005) and younger patients (median years; 50 vs 58; p = 0.012) and were detected at a more advanced stage (p = 0.027). There were no differences in location and most resections (n = 49; 51 %) were performed laparoscopically. There were no operative mortalities and 17 (17.7 %) severe complications (≥ IIIb on the Clavien-Dindo classification) were recorded with no differences between the two groups. With a median follow-up of 64.4 months (range 13.5-90), overall survival at five and ten years was 89.7 % and 72.8 % for the non-incidental tumors and 80.9 % and 54.6 % for the incidental tumors (p = ns), respectively. Disease-free survival in both groups (excluding M1a) was 71.2 % and 47.5 %, and 93.7 % and 78.1 %, respectively (p = ns). Conclusions: symptomatic tumors are more frequent in females and present at more advanced pathological stages. There were no significant differences in overall and disease-free survival between the two groups. Resection of incidental tumors ≥ 1.5-2 cm seems advisable, although each case should be assessed on an individual basis.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Cloyd JM, Poultsides GA. The Landmark Series: Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2021;28:1039-1049.
2. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589..
3. Aziz H, Howe JR, Pawlik TM. Surgery vs Observation for Patients With Small Pancreatic Neuroendocrine Tumors. JAMA Surg 2021;156:412-413. doi: 10.1001/jamasurg.2020.5640..
4. Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:1–33..
5. Hurtado-Pardo L, Cienfuegos JA, Antoñanzas J, et al. Incidental lesions of the pancreas. A clinicopathological study of 100 cases surgically treated. Revi Esp Enferm Digest 2020;112:85-89. doi: 10.17235/reed.2019.6118/2018
6. Barturen Á. Incidental pancreatic lesions - A diagnostic and management challenge. Rev Esp Enferm Digest; 2020;112:83–84.
7. Rotellar F, Pardo F, Montiel C, et al. Totally laparoscopic roux-en-Y duct-to-mucosa pancreaticojejunostomy after middle pancreatectomy: A consecutive nine-case series at a single institution. Ann Surg 2008;247:938-944.
8. Cienfuegos JA, Salguero J, Núñez-Córdoba JM, et al. Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience. Surg Endosc 2017;31:3847-3857.
9. Kimura W, Inoue T, Futakawa N, et al. Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein. Surgery 1996;120:885–890.
10. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.
11. Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery 2017;161:584–591..
12. Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007;142:761–8.
13. Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 2007;142:20–25.
14. Kloppel, G, Adsay NV, Couvelard A, et al. Pancreatic neuroendocrine neoplasms: introduction. In:WHO Classification of Tumours. Digestive System Tumours.WHO Classification of Tumours Editorial Board. 5th ed. Lyon (France) International Agency for Research on Cancer, 2019:343–346.
15. Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016;103:153–71.
16. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770–1786.
17. Wolters U, Wolf T, Stützer H, et al. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth 1996;77:217–22..
18. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes care 2012;35 Suppl 1:S64-71.
19. Crippa S, Partelli S, Zamboni G, et al. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. Surgery 2014;155:145–153.
20. Birnbaum DJ, Gaujoux S, Cherif R, et al. Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis. Surgery 2014;155:13–21.
21. Asbun HJ, Moekotte AL, Vissers FL, et al. The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. Ann Surg 2020;271:1–14.
22. Kneuertz PJ, Pitt HA, Bilimoria KY, et al. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg. 2012;16:1727–35.
23. De Rooij T, Klompmaker S, Hilal MA, et al.. Laparoscopic pancreatic surgery for benign and malignant disease. Nat. Rev. Gastroenterol. Hepatol. 2016;13:227–238. https://pubmed.ncbi.nlm.nih.gov/26882881/..
24. Finkelstein P, Sharma R, Picado O, et al. Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection. J. Gastrointest. Surg. 2017;21:855–866.
25. Sadot E, Reidy-Lagunes DL, Tang LH, et al. Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. Ann Surg Oncol 2016;23:1361–1370.
26. Kay BR, Witte DL. The impact of cancer biology, lead time bias, and length bias in the debate about cancer screening tests. J Insur Med 1991;23:102–4.
27. Kafadar K, Prorok PC. Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detected. Stat Med 2009;28:2116–2146.
28. Assi HA, Mukherjee S, Kunz PL, et al. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. The oncologist 2020;25:e276–e283. http://www.ncbi.nlm.nih.gov/pubmed/32043766..
29. Dong DH, Zhang XF, Poultsides G, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases. J Surg Oncol 2019;120:1071–1079.
30. Partelli S, Ramage JK, Massironi S, et al. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. Front Med 2020;7:1-8. http://www.ncbi.nlm.nih.gov/pubmed/33425946..
Artículos relacionados

Carta

Intestinal obstruction due to pneumatosis intestinalis

DOI: 10.17235/reed.2023.9608/2023

Carta

Síndrome carcinoide y análogos de la somatostatina

DOI: 10.17235/reed.2023.9525/2023

Editorial

Menos endoscopistas deberían hacer más CPRE

DOI: 10.17235/reed.2023.9507/2022

Imagen en Patología Digestiva

An unusual cause of a protuberant lesion of the gastric antrum

DOI: 10.17235/reed.2022.8771/2022

Imagen en Patología Digestiva

Tumor del estroma gastrointestinal gástrico abscesificado

DOI: 10.17235/reed.2022.8580/2022

Carta

Tumor de Frantz-Gruber: una neoplasia pancreática infrecuente

DOI: 10.17235/reed.2021.8345/2021

Imagen en Patología Digestiva

Endoscopic resection of a duodenal neuroendocrine tumor

DOI: 10.17235/reed.2021.8232/2021

Revisión

Revisión del diagnóstico y manejo del quiste hidatídico hepático

DOI: 10.17235/reed.2021.7896/2021

Carta

Cirugía radical en hidatidosis hepática

DOI: 10.17235/reed.2021.7743/2020

Imagen en Patología Digestiva

Duodenal diverticulum causing obstructive jaundice – Lemmel’s syndrome

DOI: 10.17235/reed.2020.7516/2020

Imagen en Patología Digestiva

A rare cause of extrahepatic biliary tract stricture: a neuroendocrine carcinoma

DOI: 10.17235/reed.2020.6491/2019

Carta

Tumor neuroendocrino simulando un tumor de Klatskin

DOI: 10.17235/reed.2019.6382/2019

Carta

Bezoar en hernia de hiato incarcerada y complicada

DOI: 10.17235/reed.2019.6159/2019

Carta

Paniculitis pancreática

DOI: 10.17235/reed.2019.6116/2018

Editorial

Safe surgery for cystic tumors of the pancreas

DOI: 10.17235/reed.2019.6042/2018

Imagen en Patología Digestiva

Neoplasia papilar mucinosa intraductal de conducto principal en un paciente con páncreas divisum

DOI: 10.17235/reed.2019.5959/2018

Carta al Editor

Consecuencias de la lesión de Dieulafoy en cirugía gástrica

DOI: 10.17235/reed.2018.5442/2017

Carta al Editor

Tumores neuroendocrinos quísticos del páncreas

DOI: 10.17235/reed.2017.5390/2017

Carta al Editor

Páncreas ectópico: una masa intestinal muy infrecuente

DOI: 10.17235/reed.2017.5353/2017

Carta al Editor

A case of a mixed adenoneuroendocrine tumor of the colon

DOI: 10.17235/reed.2017.5008/2017

Carta al Editor

Tumores neuroendocrinos de páncreas: claves para afrontar la heterogeneidad

DOI: 10.17235/reed.2017.4997/2017

Carta al Editor

Tumores neuroendocrinos de páncreas: factores pronósticos

DOI: 10.17235/reed.2017.5109/2017

Carta al Editor

Tumores neuroendocrinos pancreáticos

DOI: 10.17235/reed.2017.4725/2016

Editorial

Tumores neuroendocrinos del páncreas: no tan raros y no tan benignos

DOI: 10.17235/reed.2016.4672/2016

Original

Utilidad del balón intragástrico previo a cirugía bariátrica

DOI: 10.17235/reed.2017.4624/2016

Carta al Editor

Una forma poco común de presentación de ictericia obstructiva

DOI: 10.17235/reed.2017.4501/2016

Carta al Editor

Resección endoscópica submucosa transanal (TASER) mediante sistema TEO

DOI: 10.17235/reed.2016.4154/2015

Carta al Editor

Gastric neuroendocrine tumor presenting with gastrointestinal bleeding

DOI: 10.17235/reed.2015.3998/2015

Caso Clínico

Carcinoma epidermoide primario de recto medio: una histología atípica

DOI: 10.17235/reed.2016.3975/2015

Instrucciones para citar
Hurtado-Pardo L, Breeze C, Cienfuegos J, Benito A, Valentí V, Martí-Cruchaga P, et all. Comparison of phenotypes and outcomes following resection of incidental versus symptomatic pancreatic neuroendocrine tumors. 8096/2021


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1481 veces.
Este artículo ha sido descargado 70 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 13/05/2021

Aceptado: 12/07/2021

Prepublicado: 28/07/2021

Publicado: 07/06/2022

Tiempo de revisión del artículo: 60 días

Tiempo de prepublicación: 76 días

Tiempo de edición del artículo: 390 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas